Ubenimex for the treatment of hematological malignancies

Ubenimex for the treatment of hematological malignancies。  Multiple myeloma (multiple myeloma, MM) is a plasma cell malignant tumor, accounting for 10% of hematological malignancies, and the main age of onset is 63 to 70 years old.

In recent years, the incidence of hematological malignancies has been rising, which has severely affected the quality of life and survival of patients. Such diseases mainly include malignant lymphoma, various types of leukemia, and multiple myeloma. [1] The current treatment of hematological malignancies is still based on chemotherapy. However, the drug resistance and toxic side effects produced during the long-term chemotherapy are the main reasons for the failure of chemotherapy. Therefore, the search for drugs with low toxicity, high efficiency and antitumor activity has become a research Hot spot. [2]

Multiple myeloma (multiple myeloma, MM) is a plasma cell malignant tumor, accounting for 10% of hematological malignancies, and the main age of onset is 63 to 70 years old. The incidence of MM in some countries is increasing year by year. [3] As early as 2000, studies reported that Ubenimex can inhibit the proliferation of multiple myeloma cell lines. Ubenimex can be considered for the treatment of multiple myeloma. [4]

Another study reported that taking malignant lymphoma (ML) as the observation object, the complete remission rate of 14 patients with refractory and relapsed ML with Ubenimex capsules combined with chemotherapy was 100%. Compared with the self-control before treatment, the curative effect is very significant, the interval of chemotherapy is significantly prolonged, and the frequency of infection and cold is greatly reduced. The three indexes of immunity increased significantly compared with the previous period of treatment, suggesting that the patient’s immune function has recovered. [5]

Acute leukemia is also a common hematopoietic system disease, which is characterized by the proliferation and survival advantages of leukemia cells and the inability to differentiate and mature. Too many non-functional leukemia cells inhibit normal hematopoiesis, and invade other tissues and organs to cause dysfunction, and ultimately lead to death. Studies have found that the application of recombinant human interleukin-2 (IL-2) combined with Ubenimex (experimental group) for maintenance treatment of acute myeloid leukemia (AML) can enhance cellular immune function, interfere with tumor cell metabolism, and promote anti-tumor effector cells. Production and proliferation can reduce the recurrence of AML, improve the quality of life of patients, and significantly extend the life of patients. [6]

Ubenimex, as an aminopeptidase inhibitor, can not only enhance and regulate the body’s immunity, but also effectively inhibit the activity of CD13 on the surface of malignant hematological cells, and play a unique targeted therapy effect. If used in combination in chemotherapy Ubenimex can enhance the sensitivity of the body’s tumor cells to drugs, reduce the drug resistance rate and side effects, and its treatment of hematological malignancies will bring important clinical application value and bring clinical benefits to more patients. [2]

1. A systematic review of CAR-T cell immunotherapy for hematological malignancies. Chinese Journal of New Drugs, 2020, Volume 29, Issue 5.

2. Research progress on the effect of Ubenimex on leukemia cells. Journal of Taishan Medical College, 2012, Vol.33, No.1.

3. Observation on the efficacy of daratumomab in the treatment of relapsed/refractory multiple myeloma, Chinese General Practice, 2021, January, Volume 24, Issue 2.

4. Aminopeptidase Inhibitor Ubenimex Inhibits the Growth of Leukaemic Cell Lines and Myeloma Cells Through Its Cytotoxicity. The Journal of International Medical Research, 2000; 28: 214-221.

5. Clinical observation of domestic Ubenimex combined with chemotherapy in the treatment of refractory relapsed malignant lymphoma. Zhejiang Practical Medicine, 2000, Vol. 5, No. 6.

6. Clinical study on the maintenance treatment of acute myeloid leukemia with recombinant human interleukin-2 combined with Ubenimex. Hebei Medicine, 2013, December, Vol. 35, Issue 24.

(source:internet, reference only)

Disclaimer of medicaltrend.org